Boothbay Fund Management, LLC Arcus Biosciences, Inc. Put Options Transaction History

Boothbay Fund Management, LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $1.76 Million - $2.35 Million	-100,000 Reduced 36.27%	175,700 $3.15 Million
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $1.77 Million - $2.3 Million	104,400 Added 60.95%	275,700 $5.6 Million
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $1.83 Million - $2.66 Million	114,900 Added 203.72%	171,300 $3.12 Million
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $1.11 Million - $2.01 Million	56,400 New	56,400 $1.17 Million
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $2.12 Million - $4.65 Million	-123,200 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$28.92 - $41.83 $2.68 Million - $3.87 Million	92,600 Added 302.61%	123,200 $3.89 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $960,228 - $1.48 Million	30,600 New	30,600 $1.24 Million
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $772,891 - $1.08 Million	-28,700 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$22.75 - $35.77 $652,925 - $1.03 Million	28,700 New	28,700 $788,000

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.14B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.